Gracell Biotechnologies Inc. (NASDAQ:GRCL) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET

Company Participants

William Cao - Chairman, Chief Executive Officer

Wendy Li - Chief Medical Officer

Kevin Xie - Chief Financial Officer

Conference Call Participants

Kelly Shi - Jefferies

Joe Cantanzaro - Piper Sadler

Justin Zelin - BTIG

Emily Bodnar - Wainwright

Yigal Nochomovitz - Citigroup

Operator

Ladies and gentlemen, thank you for standing by. My name is Bhavesh, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Gracell Biotechnologies Second Quarter 2023 Earnings Conference Call. At this time, all lines have been placed on mute to prevent any background noise. [Operator Instructions]

Thank you. I will now hand the call over to Kevin Xie. You may begin your conference.

Kevin Xie

Good morning and welcome to Gracell’s second quarter 2023 corporate update conference call on the webcast. With me today are Gracell’s founder and the Chief Executive Officer, Dr. William Cao, and our chief medical officer, Dr. Wendy Li. We're excited to discuss the advancement of the trials underway with our CAR-T candidates on today's call. We also look forward to sharing with you our recent business developments and upcoming objectives as we progress through 2023.

We will conduct a question-and-answer session following our formal remarks. This morning, we issued a press release announcing unaudited financial results for the second quarter ending June 30, 2023. We encourage everyone to read this press release and would also like to remind you that this call is being recorded for replay.

Please note that for certain information discussed on the call today, including financial data, clinical data, and the future plans of our program, Gracell’s management will be making forward-looking statements. Actual results could differ materially from those stated or implied by those forward-looking statements as a result of various important factors.

Please refer to the risk factors section of our latest 20-F filing with SEC for a full disclosure of these risks and factors. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, August 14, 2023. Gracell undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities law.

I will now turn the call over to Gracell’s CEO, Dr. William Cao. William?